Syngene International Limited — PPTs, 17-12-2025: Investor Presentation

Syngene's T&CR (Translational & Clinical Research) business is positioned in a booming global Clinical CRO market, estimated at $59 billion in 2024 and projected to reach $99 billion by 2029 (11% CAGR). India's clinical CRO segment shines, forecast for 16% CAGR ($1.9 billion in 2024 to $3.4 billion by 2028), fueled by vast patient pools and cost benefits.

Syngene's strategy involves strengthening its T&CR portfolio, tackling complex new modality trials, and integrating into later clinical trial phases. This leverages their integrated platform for seamless transitions and faster drug development, aiming for reduced risk.

A key recent win: Syngene landed its first global Phase III clinical trial with a US biotech. This multi-country trial (India/US) highlights their expanding global clinical capabilities.

Management sees a strong "right to win" for Syngene in India's fragmented market, backed by deep experience, regulatory excellence, and global compliance. T&CR is positioned as a comprehensive clinical partner across the drug development journey.